Diagnostik og behandling af neuromyelitis optica

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease characterized by antibodies against aquaporin-4 in up to 80% of the cases and even less in the NMO spectrum disorders, which may be difficult to distinguish from early multiple sclerosis. While immunosuppressive therapy should be introduced in definite NMO, treatment strategies of NMO spectrum disorders are less clearly defined. Here, we review the current guidelines for treatment of NMO and NMO spectrum disorders in the light of two cases, and suggest a practical approach to the management of these disorders.

Original languageEnglish
JournalUgeskrift for Laeger
Volume176
Issue number26
Pages (from-to)1220-1224
ISSN0041-5782
Publication statusPublished - 23. Jun 2014

Fingerprint

Neuromyelitis Optica
Demyelinating Diseases
Immunosuppressive Agents
Guidelines

Cite this

@article{530e288c2e554741826a2645ec0309aa,
title = "Diagnostik og behandling af neuromyelitis optica",
abstract = "Neuromyelitis optica (NMO) is an inflammatory demyelinating disease characterized by antibodies against aquaporin-4 in up to 80{\%} of the cases and even less in the NMO spectrum disorders, which may be difficult to distinguish from early multiple sclerosis. While immunosuppressive therapy should be introduced in definite NMO, treatment strategies of NMO spectrum disorders are less clearly defined. Here, we review the current guidelines for treatment of NMO and NMO spectrum disorders in the light of two cases, and suggest a practical approach to the management of these disorders.",
author = "Nielsen, {Helle Hvilsted} and Mads Ravnborg and Zsolt Illes",
year = "2014",
month = "6",
day = "23",
language = "English",
volume = "176",
pages = "1220--1224",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "26",

}

Diagnostik og behandling af neuromyelitis optica. / Nielsen, Helle Hvilsted; Ravnborg, Mads; Illes, Zsolt.

In: Ugeskrift for Laeger, Vol. 176, No. 26, 23.06.2014, p. 1220-1224.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Diagnostik og behandling af neuromyelitis optica

AU - Nielsen, Helle Hvilsted

AU - Ravnborg, Mads

AU - Illes, Zsolt

PY - 2014/6/23

Y1 - 2014/6/23

N2 - Neuromyelitis optica (NMO) is an inflammatory demyelinating disease characterized by antibodies against aquaporin-4 in up to 80% of the cases and even less in the NMO spectrum disorders, which may be difficult to distinguish from early multiple sclerosis. While immunosuppressive therapy should be introduced in definite NMO, treatment strategies of NMO spectrum disorders are less clearly defined. Here, we review the current guidelines for treatment of NMO and NMO spectrum disorders in the light of two cases, and suggest a practical approach to the management of these disorders.

AB - Neuromyelitis optica (NMO) is an inflammatory demyelinating disease characterized by antibodies against aquaporin-4 in up to 80% of the cases and even less in the NMO spectrum disorders, which may be difficult to distinguish from early multiple sclerosis. While immunosuppressive therapy should be introduced in definite NMO, treatment strategies of NMO spectrum disorders are less clearly defined. Here, we review the current guidelines for treatment of NMO and NMO spectrum disorders in the light of two cases, and suggest a practical approach to the management of these disorders.

M3 - Journal article

C2 - 25294570

VL - 176

SP - 1220

EP - 1224

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 26

ER -